德拉维尔治疗公司的高管在2026年2月3日出售股票,因为股票略有下跌. Executives at Travere Therapeutics sold shares on February 3, 2026, as stock dipped slightly.

2026年2月3日,Travere Therapeutics (TVTX) 的多名内部人士出售股票,包括首席执行官埃里克·杜布,首席财务官克里斯托弗·克莱恩,首席会计官桑德拉·卡尔文,彼得·希尔玛和伊丽莎白·里德,共同减少了他们的股份. On February 3, 2026, multiple insiders at Travere Therapeutics (TVTX) sold shares, including CEO Eric Dube, CFO Christopher Cline, Chief Accounting Officer Sandra Calvin, Peter Heerma, and Elizabeth Reed, collectively reducing their stakes. 该公司的股票关闭额为32.84美元,下降0.26美元,交易额低于平均水平。 The company’s stock closed at $32.84, down $0.26, with below-average trading volume. Travere是一家以稀有肾脏和遗传疾病为重点的圣地亚哥生物制药公司,市场上限为29.4亿美元,其主要药物稀释剂获得林业发展局加速批准。 Travere, a San Diego-based biopharma firm focused on rare kidney and genetic disorders, has a market cap of $2.94 billion and its lead drug sparsentan received accelerated FDA approval. 分析员维持协商一致的“购买模式”评级,目标价格为38.86美元。 Analysts maintain a consensus “Moderate Buy” rating with a target price of $38.86.